Product custom-nanocomposites-nanopeptides

Home > products > custom-nanocomposites> nanopeptides

Catalog	name	Description	price
R-Mcs-516	RVG29 modified liposomes@Nattokinase	Liposomal loaded Nattokinase modified with RVG29 is a cutting-edge brain targeted nanodelivery system aimed at efficiently delivering thrombolytic enzymes through the blood-brain barrier (BBB) for the prevention or adjuvant treatment of ischemic stroke, cerebral microthrombi, and related neurodegenerative diseases.	price>
R-Mcs-517	Nintedanib and Dexamethasone@Liposomal CY5.5,100-150nm	Nintedanib and Dexamethasone@Liposomal CY5.5,100-150nm/Liposome@with Nintedanib and Dexamethasone modified CY5.5 is a multifunctional targeted nano delivery system that achieves synergistic anti fibrotic and anti-inflammatory effects through liposome encapsulated dual drugs, and uses CY5.5 near-infrared fluorescence labeling to achieve real-time visualization tracking of in vivo distribution. It is mainly used for the study of acute exacerbation of pulmonary fibrosis (AE-IPF) or tumor related fibrosis microenvironment.	price>
R-Mcs-545	RGD modified macrophage membrane encapsulating hollow manganese dioxide@L-Arg	RGD modified macrophage membrane encapsulating hollow manganese dioxide@L-Arg/RGD-macrophage membrane encapsulating hollow manganese dioxide loaded L-Arg is a new bionic nano drug delivery system, which combines targeting, responsive release and immune regulation functions, showing potential for synergistic treatment in tumor treatment, atherosclerosis and other inflammatory diseases.	price>
R-Mcs-546	HMnO2@L-Arg	HMnO2@L-Arg is a multifunctional nanosystem based on hollow manganese dioxide (HMnO ₂) nanocarriers loaded with L-arginine(L-Arg). It has the potential for responsive drug release, microenvironment regulation, and imaging guidance, and is widely used in the treatment of inflammatory diseases and tumors.	price>
R-Mcs-547	CSTSMLKAC modified liposomes@glycine,100-200nm	CSTSMLKAC modified liposomes@glycine,100-200nm is a targeted nano delivery system with the ability to specifically identify myocardial injury areas, suitable for research and treatment exploration related to cardiovascular diseases.	price>
R-Mcs-548	Peptide CSTSMLKAC modified blank liposomes,100-200nm	Peptide CSTSMLKAC modified blank liposomes,100-200nm, is a nanocarrier system with myocardial targeting ability, mainly used as a control carrier or functional platform in scientific research.	price>
R-Mcs-551	Liposome@peptide(PKPREP-K(FITC)),100nm	Liposome@peptide PKPREP-K (FITC), 100nm is an intelligent nano delivery platform that integrates targeting, tracking, and drug loading, particularly suitable for precision medicine research that requires real-time monitoring of the delivery process.	price>
R-Mcs-555	Peptide WYRGRL-liposomes@astaxanthin and DIR (100nm)	Peptide WYRGRL-liposomes@astaxanthin and DIR(100nm) are a precise targeted nanoscale active substance delivery carrier that combines the targeting properties of cartilage affinity peptides, the biological activity of astaxanthin, and the excellent delivery performance of liposomes. At the same time, DIR (lipophilic fluorescent dye) is used for visual tracing, providing an innovative tool that combines functionality and traceability for biomedical research and clinical translation.	price>
R-Mcs-561	Black phosphorus nanosheets modified peptides AVHS@RWWRWW	Black phosphorus nanosheets modified peptides AVHS@RWWRWW/Black phosphorus nanosheets modified peptides(Ala-Val-His-Ser-Arg-Trp-Trp-Arg-Trp-Trp) is a novel nanocomposite that can be used for antibacterial therapy, tumor targeted combination therapy, and intelligent responsive drug delivery.Ala-Val-His-Ser-Arg-Trp-Trp-Arg-Trp-Trp,abbreviated as AVHS@RWWRWW.	price>
R-M1-cs8806	RVG29 modified liposomes loaded with paclitaxel	The RVG29 modification on the liposomes provides a targeted approach to deliver paclitaxel specifically to neuronal cells, potentially for the treatment of neurological disorders or brain tumors. The RVG29 peptide interacts with nAChR on neuronal cells, promoting the endocytosis of the liposomes and subsequent release of the paclitaxel within the targeted cells.RVG29 modified liposomes loaded with paclitaxel offer the benefit of targeted drug delivery to neuronal cells, improving the efficacy and selectivity of paclitaxel treatment.RVG29 is a peptide derived from the rabies virus glycoprotein, which has a high affinity for the neuronal acetylcholine receptor (nAChR), specifically present on neuronal cells. By modifying liposomes with RVG29, they can be targeted specifically to neuronal cells, allowing for enhanced drug delivery to these cells.	price>

...